This article is more than 5 years old. Information may no longer be current.
Pfizer begins phase 2 trial of experimental glaucoma treatment
SOPHIA ANTIPOLIS, France — Pfizer has initiated a dose-ranging phase 2 clinical study of an experimental glaucoma treatment in Japan, according to a press release from development partner NicOx.
The treatment, called PF-03187207, contains nitric oxide-donating prostaglandin F2-alpha analogs for the reduction of IOP and was co-developed by Pfizer and NicOx, the release said.
In the trial, researchers will compare the safety and efficacy of PF-03187207 with Xalatan (latanoprost, Pfizer) after randomly assigning doses of either drug to approximately 120 Japanese patients with primary open-angle glaucoma or ocular hypertension in one or both eyes.
The treatment is currently in an ongoing phase 2 proof-of-concept study in the United States, the release said.